Assistant Professor, Department of Obstetrics & Gynecology, Aretaieion Hospital, Athens University, Athens, Attiki, Greece.
Assistant Professor, Department of Surgery, Ippokrateion General Hospital, Athens University, Athens, Attiki, Greece.
Associate Professor, Department of Biologic Chemistry, Athens University, Athens, Attiki, Greece.
Professor, Department of Surgery, Ippokrateion General Hospital, Athens University, Athens, Attiki, Greece.
Director, Experimental Research Centre ELPEN Pharmaceuticals, S.A. Inc., Co., Pikermi, Attiki, Greece.
Aim: This study compared the attenuatin effects of erythropoietin (Epo) and antioxidant drug U-74389G based on 2 preliminary studies. The provided results on blood platelet counts were co-evaluated in a hypoxia reoxygenation protocol of an animal model.
Materials and methods: Blood platelet counts were evaluated at the 60th reoxygenation min (for groups A, C and E) and at the 120th reoxygenation min (for groups B, D and F) in 60 rats. Groups A and B received no drugs, rats from groups C and D were administered with Epo; whereas rats from groups E and F were administered with U-74389G.
Results: The first preliminary study recommended a non-significant attenuating effect of Epo (p-value=0.9725). The second preliminary study also recommended a more powerful attenuating effect of U-74389G (p-value=0.0857). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that U-74389G has at least 37-fold more attenuating action than Epo (p-value=0.0000).
Conclusions: The hematologist must be informed about the effective attenuating potencies of U-74389G in related coagulant and clotting situations.